Coming Soon! Lipid management highlights from AHA 2025

Dr Robert P. Giugliano is a Senior Investigator with the Thrombolysis in Myocardial Infarction (TIMI) Study Group, Staff Physician in the Cardiovascular Division at the Brigham and Women’s Hospital and Professor of Medicine at Harvard Medical School, Boston, USA. He graduated summa cum laude and phi beta kappa from Dartmouth College, and received his medical degree at Harvard Medical School. Dr Giugliano completed his internship, residency and chief residency at Cedars-Sinai Medical Centre, Los Angeles, USA, and then returned to Boston as a Cardiology Fellow at the Massachusetts General Hospital, USA.  

His research interests include novel lipid-lowering therapies, antithrombotic therapies for atrial fibrillation and acute coronary syndromes (ACS), and the assessment of outcomes in patients with ACS. Dr Giugliano has authored more than 360 original articles and 250 reviews/editorials/book chapters. He is the Founding Scientific Advisor and Editor-in-Chief for MD Conference Express, Co-Editor-in-Chief of Cardiology and Therapy, and serves on editorial boards for Circulation, The American Heart Journal, Clinical Cardiology, Cor et Vasa, Hospital Practice, Cardiovascular Therapeutics and Clinical Pathways in Cardiology. 

Dr Giugliano is the Principal TIMI Investigator for over a dozen clinical trials including the VESALIUS-CV trial with evolocumab, ENGAGE AF-TIMI 48 trial with edoxaban, and Executive Committee member of several additional trials including the IMPROVE-IT (ezetimibe), FOURIER (evolocumab), AZALEA-TIMI 71 (abelacimab) and CORE trials (olezarsen) trials. 

 Ulrich Laufs is Professor and Chief of Cardiology at Leipzig University Hospital. After completing his training at the Universities of Bochum and Hamburg, he was resident at the University of Cologne and spent two years as post-doctoral researcher at Harvard University in Boston. Before moving to Leipzig in 2017, he was Professor for Clinical and Experimental Medicine and Vice-chairman of the Department of Internal Medicine, Cardiology, Angiology and Intensive Medicine at the University of Saarland in Homburg. 

Professor Laufs heads a research group focused on cellular and molecular mechanisms, and clinical studies of cardiovascular prevention with a special interest in lipid disorders. Additional research interests of the department include heart failure and cardiomyopathies, cardiac imaging, interventional cardiology and atrial fibrillation. He has > 600 publications listed medline that have been cited >40,000 times (H-index ~100). 

Laufs serves on the boards of the German Society of Cardiology (DGK) and the D•A•CH-Gesellschaft Herz-Kreislauf-Prävention, the federal drug commission of German Pharmacists and in several editorial boards of cardiovascular journals, including the European Heart Journal. He is the secretary of the European Society of Atherosclerosis (EAS). His honors include the Population Sciences Award of the European Society of Cardiology, the Paul Martini Award, and the Albert Fraenkel Award of the German Cardiac Society.